CuriMeta
Financials
Estimates*
USD | 2022 | 2023 |
---|---|---|
Revenues | <1m | 1.4m |
% growth | - | 200 % |
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | Seed | |
* | $6.0m | Seed | |
Total Funding | €5.5m |
Related Content
Recent News about CuriMeta
EditCuriMeta is a data-driven startup that operates in the healthcare and life sciences sector. The company's primary function is to facilitate and expedite scientific research by providing researchers with access to real-world, anonymized health data. This data is curated, enhanced, and transformed to provide invaluable insights that can help solve pressing scientific and clinical challenges.
CuriMeta's clients are primarily researchers and collaborators in the biopharmaceutical and life science industries. The company's services are particularly beneficial for these clients as they often require complex and hard-to-source data types, such as genetic variants, radiology, and pathology data, to advance their studies.
The business model of CuriMeta revolves around the collection, processing, and provision of advanced real-world data. This data is generated by health systems and academic medical centers, and CuriMeta makes it accessible to researchers. The company's services are crucial in accelerating the pace of research and advancing the science of medicine.
CuriMeta generates revenue by providing these data services to its clients. The company offers a range of services, including non-interventional retrospective and prospective studies, novel clinical trial designs, external control arms, and training data sets to support AI development.
In summary, CuriMeta is a strategic partner for researchers in the healthcare and life sciences sector, providing them with the necessary data to accelerate their studies and develop life-saving health interventions.
Keywords: Real-world health data, Biopharmaceutical research, Life science research, Data curation, Data enhancement, Data transformation, Advanced real-world data, Non-interventional studies, Clinical trial designs, AI development.